There are 2949 resources available
356TiP - A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009
Presenter: Hope Rugo
Session: E-Poster Display
Resources:
Abstract
355TiP - Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC)
Presenter: Nicholas Turner
Session: E-Poster Display
Resources:
Abstract
357TiP - SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Presenter: Javier Cortés
Session: E-Poster Display
Resources:
Abstract
358TiP - Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer
Presenter: Aditya Bardia
Session: E-Poster Display
Resources:
Abstract
359TiP - International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)
Presenter: Peter Kaufman
Session: E-Poster Display
Resources:
Abstract
374P - Temozolamide (TMZ) rechallenge at standard or metronomic dose versus other treatments in patients (pts) with high grade glioma with TMZ free-interval (TFI) longer than 3 months (mo)
Presenter: Alejandro Garcia-Alvarez
Session: E-Poster Display
Resources:
Abstract
375P - Chemotherapy options for recurrent glioblastoma
Presenter: Alexander Pawsey
Session: E-Poster Display
Resources:
Abstract
376P - The efficacy and safety of CyberKnife combined with bevacizumab and temozolomide in the treatment of recurrent high-grade glioma
Presenter: Kang Jingbo
Session: E-Poster Display
Resources:
Abstract
377P - Long-term survival following photodynamic therapy for malignant glioma depending on MGMT status
Presenter: Artemii Rynda
Session: E-Poster Display
Resources:
Abstract
378P - MGMT status influences prognosis of patients with IDH wild type grade III gliomas
Presenter: Enrico Franceschi
Session: E-Poster Display
Resources:
Abstract